quifenadine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
4748 10447-39-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • quifenadine
  • quifenadine hydrochloride
  • phencarol
  • quifenadine HCl
  • Molecular weight: 293.41
  • Formula: C20H23NO
  • CLOGP: 3.18
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 23.47
  • ALOGS: -3.72
  • ROTB: 3

Drug dosage:

None

ADMET properties:

None

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 1.114 Moderate 0.68
caco2-efflux Caco-2 efflux ratio (BA/AB) 3.926 Moderate 0.68
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 10.940 10^-6 cm/s Moderate 0.68
dh-clint Dog hepatocyte intrinsic clearance 6.950 uL/min/10^6 cells Moderate 0.68
dppb Dog plasma protein binding (% unbound) 36.950 % Moderate 0.68
fcs-ppb Fetal calf serum protein binding (% unbound) 59.050 % Moderate 0.68
herg hERG pIC50 5.173 pIC50 Moderate 0.68
hh-clint Human hepatocyte intrinsic clearance 2.698 uL/min/10^6 cells Moderate 0.68
hlm-clint Human liver microsomal intrinsic clearance 7.727 uL/min/mg protein Moderate 0.68
hppb Human plasma protein binding (% unbound) 49.020 % Moderate 0.68
kinase-safety-class ACVR2A,ACVR2B,AKT2,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,ITK,JAK2,MAP3K7,MAPK12,MAPK7,MET,NTRK2,PDK2,PDK4,PIM2,PRKDC,SIK2,SIK3,TEK,TGFBR1 33
kinase-selectivity-class AXL,ERBB2,GRK2,PDK4,PIK3CD,SIK2 6
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 2.388 Moderate 0.68
mh-clint Mouse hepatocyte intrinsic clearance 58.210 Moderate 0.68
mppb Mouse plasma protein binding (% unbound) 39.890 Moderate 0.68
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 6.699 Moderate 0.68
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 54.990 % Moderate 0.68
rh-clint Rat hepatocyte intrinsic clearance 90.573 uL/min/10^6 cells Moderate 0.68
rh-fuinc Rat hepatocyte fraction unbound in incubation 67.980 % Moderate 0.68
rppb Rat plasma protein binding (% unbound) 43.080 % Moderate 0.68
solubility-dd Solubility at pH 7.4 in DMSO 905.733 uM Moderate 0.68

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC R06AX31 RESPIRATORY SYSTEM
ANTIHISTAMINES FOR SYSTEMIC USE
ANTIHISTAMINES FOR SYSTEMIC USE
Other antihistamines for systemic use
MeSH PA D006633 Histamine Antagonists
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018494 Histamine Agents

Related Drugs by ATC class:

R06AX Other antihistamines for systemic use 26 drugs
acrivastineantazolineastemizoleazatadineazelastinebamipinebilastinecyproheptadinedeptropinedesloratadineebastineepinastine show all 26 →

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Allergic rhinitis indication 61582004
Sneezing indication 76067001
Seasonal allergic rhinitis indication 367498001
Allergic conjunctivitis indication 473460002 DOID:11204




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.8 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

None

External reference:

IDSource
D10230 KEGG_DRUG
CHEBI:134746 CHEBI
CHEMBL1187694 ChEMBL_ID
C014742 MESH_SUPPLEMENTAL_RECORD_UI
10447-38-8 SECONDARY_CAS_RN
DB13713 DRUGBANK_ID
W9A18RJ49B UNII
C0243449 UMLSCUI
4714 INN_ID
65600 PUBCHEM_CID

Pharmaceutical products:

None